История выручки, прибыли и денежных потоков из официальной финансовой отчётности.
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.
Интерактивные графики и полная отчётность → Модель оценки (DCF) →
| Отчёт о прибылях и убытках | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Общая выручка | $3.3B | $3.1B | $2.9B | $3.0B | $2.9B | $2.8B | $2.1B | $1.8B | $1.7B | $1.6B | $1.5B | $1.4B | $1.4B | $1.4B | $1.3B | $1.2B | $1.1B | $1.1B | $1.1B | $1.0B | $913M |
| Валовая прибыль | $1.2B | $1.1B | $1.0B | $1.1B | $1.1B | $1.2B | $768M | $609M | $546M | $513M | $501M | $456M | $448M | $435M | $388M | $339M | $318M | $304M | $303M | $292M | $262M |
| Валовая маржа % | 36.8% | 35.9% | 34.6% | 38.4% | 39.5% | 41.4% | 35.8% | 33.0% | 31.8% | 32.1% | 33.2% | 32.6% | 31.5% | 31.8% | 30.6% | 28.4% | 28.7% | 28.8% | 28.8% | 28.6% | 28.7% |
| Операционная прибыль (EBIT) | $700M | $617M | $595M | $711M | $764M | $759M | $419M | $297M | $255M | $229M | $197M | $129M | $182M | $162M | $136M | $116M | $106M | $106M | $125M | $113M | $106M |
| Операционная маржа % | 21.1% | 20.1% | 20.6% | 24.1% | 26.5% | 26.8% | 19.5% | 16.1% | 14.8% | 14.3% | 13.0% | 9.2% | 12.8% | 11.9% | 10.8% | 9.7% | 9.6% | 10.0% | 11.8% | 11.1% | 11.6% |
| Чистая прибыль | $565M | $494M | $493M | $593M | $586M | $662M | $346M | $242M | $207M | $151M | $144M | $96M | $127M | $112M | $81M | $76M | $65M | $73M | $86M | $71M | $67M |
| Чистая маржа % | 17.0% | 16.1% | 17.0% | 20.1% | 20.3% | 23.4% | 16.1% | 13.1% | 12.0% | 9.4% | 9.5% | 6.8% | 8.9% | 8.2% | 6.4% | 6.3% | 5.9% | 6.9% | 8.2% | 6.9% | 7.3% |
| EBITDA | — | $724M | $744M | $844M | $808M | $880M | $519M | $403M | $353M | $326M | $288M | $218M | $272M | $248M | $200M | $183M | $161M | $166M | $186M | $158M | $150M |
| Прибыль на акцию (EPS) | $7.82 | $6.79 | $6.69 | $7.88 | $7.73 | $8.67 | $4.57 | $3.21 | $2.74 | $1.99 | $1.91 | $1.30 | $1.75 | $1.57 | $1.12 | $1.02 | $0.89 | $1.00 | $1.19 | $0.98 | $1.00 |
| Акции в обращении (M) | — | 73M | 74M | 75M | 76M | 76M | 76M | 75M | 75M | 76M | 75M | 74M | 73M | 71M | 72M | 74M | 73M | 73M | 72M | 72M | 67M |
Источник: публичная отчётность компании (SEC). Сверяйте с SEC EDGAR, прежде чем полагаться на любую цифру.
Балансы, денежные потоки, квартальные данные и финансовые коэффициенты — в интерактивном просмотрщике WST. /companies/us/WST
Информация на сайте предназначена исключительно для образовательных и информационных целей и не является инвестиционной рекомендацией. Целевые цены и рекомендации не публикуются.
About TickerBase · Data methodology & sources · Privacy · Terms